Results 191 to 200 of about 21,799 (237)

Does the Korean economy depend too much on Samsung? [PDF]

, 2015
Kim, Hyoung Tae
core  

Successful Immune Checkpoint Inhibitor Rechallenge After Sintilimab-Induced Pancreatitis: A Case Report. [PDF]

Int Med Case Rep J
Shi H, Ye L, Mo Q, Li R, Yu Y.
europepmc   +1 more source

Biosimilar Versus Innovator Ranibizumab in Myopic CNVM: Comparative Real-World Outcomes- The BRIM Study. [PDF]

Clin Ophthalmol
Chakraborty D, Sinha TK, Sinha S, Biswas RK, Maiti A, Nandi K, Rungta D, Bhattacharya R.   +7 more
europepmc   +1 more source

Efficacy & safety of adalimumab biosimilar in axial spondyloarthritis: A retrospective study from a tertiary care centre in South India. [PDF]

Indian J Med Res
Gopalan A, Gavali M, Yerram K.
europepmc   +1 more source

Comparative efficacy of intravitreal aflibercept biosimilar QL1207 versus reference aflibercept in the treatment of diabetic macular edema. [PDF]

Front Med (Lausanne)
Zhai G, Liu N, Wang S, Zhang X.
europepmc   +1 more source

Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.

JAMA Netw Open
Abdelaziz A, Winn AN, Dusetzina SB, Mitchell AP.   +3 more
europepmc   +1 more source

Originator versus biosimilar adalimumab in hidradenitis suppurativa: A multicenter real-world analysis of clinical response, maintenance of response, and switching. [PDF]

JAAD Int
Aghajani M, Pham J, Sholji T, Burrell K, Kok C, Frew JW.   +5 more
europepmc   +1 more source

Scoping review of biosimilar disease-modifying antirheumatic drugs in pregnancy: evidence gaps and proposed outcome reporting framework. [PDF]

Rheumatol Int
Cheng V, Amiri N, Cheng V, Ellis U, Cragg JJ, Proulx L, Tucker DR, De Vera MA.   +7 more
europepmc   +1 more source

Using machine learning algorithms to optimize treatment with high-cost biologics in a national cohort of patients with inflammatory bowel disease. [PDF]

JAMIA Open
Hou JK, Tang TM, Sansgiry S, Van T, Richardson PA, Pham C, Cunningham F, Baker JA, Zhu J, Waljee AK.   +9 more
europepmc   +1 more source

​Did a Non-Medical Biosimilar Switching Policy Cause an Increase in Non-Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis? [PDF]

Arthritis Care Res (Hoboken)
Dang H, Blitz S, Bansback N, Law M, Harrison M.   +4 more
europepmc   +1 more source